|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ID** | **Name** | **Drug/Intervention** | **Phase** | **Recruiting/Stage** | **Combination of at least one immune checkpoint inhibitor/co-stimulator with** |
|  | Immunotherapy | Chemo- or Radiotherapy | Targeted Therapy | Others |
| NCT01621490 | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1) | **Nivolumab****Ipilimumab** | 1 | Yes | X |  |  |  |
| NCT01844505 | Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | **Nivolumab****Ipilimumab**Placebo | 3 | Ongoing butnot recruiting | X |  |  |  |
| NCT02553642 | Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | **Nivolumab****Ipilimumab** | 2 | Yes | X |  |  |  |
| NCT02519322 | Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma | **Ipilimumab****Nivolumab** | 2 | Not yet | X |  |  |  |
| NCT01783938 | Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) | **Nivolumab****Ipilimumab** | 2 | Ongoing butnot recruiting | X |  |  |  |
| NCT02186249 | Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Subjects With Unresectable or Metastatic Melanoma (CheckMate 218) | **Nivolumab****Ipilimumab** |  | Expanded access | X |  |  |  |
| NCT01927419 | Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma (CheckMate 069) | **Nivolumab****Ipilimumab**Placebo | 2 | Ongoing butnot recruiting | X |  |  |  |
| NCT02523313 | Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED | **Nivolumab****Ipilimumab**Placebo | 2 | Yes | X |  |  |  |
| NCT01024231 | Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | **Nivolumab****Ipilimumab** | 1 | Ongoing butnot recruiting | X |  |  |  |
| NCT02259231 | RTA 408 Capsules in Patients With Melanoma - REVEAL | **Ipilimumab****Nivolumab** Omaveloxolone | 1/2 | Yes | X |  |  |  |
| NCT01176474 | A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma | **Nivolumab****Ipilimumab**NY-ESO-1 157-165gp100:280-288Montanide ISA 51  | 1 | Ongoing butnot recruiting | X |  |  |  |
| NCT02374242 | Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases (ABC) | **Nivolumab****Ipilimumab** | 2 | Yes | X |  |  |  |
| NCT02320058 | A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204) | **Ipilimumab****Nivolumab** | 2 | Yes | X |  |  |  |
| NCT02437279 | Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (OpACIN) | **Ipilimumab****Nivolumab**Surgery | 1 | Yes | X |  |  |  |
| NCT02460068 | A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis (NIBIT-M2) | **Ipilimumab****Nivolumab**Fotemustine | 3 | Yes | X | X |  |  |
| NCT02631447 | Sequential Combo Immuno and Target Therapy (SECOMBIT) Study | **Nivolumab****Ipilimumab**LGX818MEK162 | 2 | Not yet | X |  | X |  |
| NCT02535078 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma | **Durvalumab****Tremelimumab** IMCgp100 | 1b/2 | Not yet | X |  |  |  |
| NCT02174172 | A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors | **Ipilimumab****MPDL3280A**IFN-a2b | 1 | Yes | X |  |  |  |
| **ID** | **Name** | **Intervention** | **Phase** | **Recruiting/stage** | **Combination of at last one immune checkpoint inhibitor/****co-stimulator with** |
|  | Immunotherapy | Chemo- or Radiotherapy | Targeted therapy | Others |
| NCT02089685 | Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | **Pembrolizumab****Ipilimumab**PegIFN-2b | 1/2 | Ongoing butnot recruiting | X |  |  |  |
| NCT02460224 | Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | **LAG525****PDR001** | 1/2 | Not yet | X |  |  |  |
| NCT01968109 | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | **BMS-986016****BMS-936558** | 1 | Yes | X |  |  |  |
| NCT02178722 | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037) | **MK-3475****INCB024360** | 1/2 | Yes | X |  |  |  |
| NCT02471846 | A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | **GDC-0919****MPDL3280A** | 1 | Yes | X |  |  |  |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | **Varlilumab****Atezolizumab** | 1/2 | Not yet | X |  |  |  |
| NCT02335918 | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | **Varlilumab****Nivolumab** | 1/2 | Yes | X |  |  |  |
| NCT02475213 | Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer | **MGA271****Pembrolizumab** | 1 | Yes | X |  |  |  |
| NCT02554812 | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | **Avelumab****PF-05082566** | 1b/2 | Not yet | X |  |  |  |
| NCT02575404 | GR-MD-02 Plus Pembrolizumab in Melanoma Patients | **GR-MD-02****Pembrolizumab** | 1 | Not yet | X |  |  |  |
| NCT01714739 | A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors | **Lirilumab****Nivolumab** | 1 | Yes | X |  |  |  |
| NCT02381314 | Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer | **MGA271****Ipilimumab** | 1 | Yes | X |  |  |  |
| NCT01103635 | Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | **CP-870,893****Tremelimumab** | 1 | Completed | X |  |  |  |
| NCT01604889 | A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma | **INCB024360****Ipilimumab**Placebo | 1/2 | Ongoing butnot recruiting | X |  |  |  |
| NCT02413827 | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma | **Varlilumab****Ipilimumab** | 1/2 | Yes | X |  |  |  |
| NCT01750580 | Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor | **Lirilumab****Ipilimumab** | 1 | Completed | X |  |  |  |
| NCT02318277 | A Study of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors | **MEDI4736****INCB024360** | 1/2 | Yes | X |  |  |  |
| NCT02643303 | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | **Durvalumab****Tremelimumab**Poly ICLC | 1/2 | Not yet | X |  |  |  |
| NCT02073123 | Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma | **Indoximod****Ipilimumab** | 1/2 | Yes | X |  |  |  |
| NCT02054520 | Immunotherapy Study for Patients With Stage IV Melanoma | **Ipilimumab****Pembrolizumab****Nivolumab** HyperAcute®-Melanoma (HAM) Immunotherapy | 2b | Yes | X |  |  |  |
| NCT00020540 | Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer | **recombinant CD40-L**recombinant Flt3-L | 1 | Completed | X |  |  |  |
| NCT01961115 | INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | **INCB024360**MELITAC 12.1 Vaccine | 2 | Yes | X |  |  |  |
| **ID** | **Name** | **Intervention** | **Phase** | **Recruiting/stage** | **Combination of at last one immune checkpoint inhibitor/****co-stimulator with** |
|  | Immunotherapy | Chemo- or Radiotherapy | Targeted therapy | Others |
| NCT02515227 | Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab (Mel64;PATHVACS) | **Pembrolizumab**6MHP | 1/2 | Not yet | X |  |  |  |
| NCT02498756 | Cytokine-induced Killer Study for Patients With Stage II Melanoma | **Ipilimumab**Cytokine-induced killer cells | 2 | Not yet | X |  |  |  |
| NCT01176461 | Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 | **BMS-936558**MART-1NY-ESO-1gp100:209-217(210M)gp100:280-288(288V)Montanide ISA 51 VG | 1 | Yes | X |  |  |  |
| NCT02574533 | Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma | **Pembrolizumab**Vigil | 1 | Yes | X |  |  |  |
| NCT02526017 | Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers (FPA008-003) | **Nivolumab**FPA008 | 1 | Yes | X |  |  |  |
| NCT02565992 | Phase I Study of Intratumoral CAVATAK™ and Pembrolizumab in Subjects With Advanced Melanoma (CAPRA) | **Pembrolizumab** CAVATAK | 1 | Not yet | X |  |  |  |
| NCT02263508 | Pembrolizumab (MK-3475) With or Without Talimogene Laherparepvec in Unresected Melanoma | **Pembrolizumab** talimogene laherparepvec | 3 | Ongoing butnot recruiting | X |  |  |  |
| NCT02272855 | A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma | **Ipilimumab**HF10 | 2 | Yes | X |  |  |  |
| NCT02275416 | Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma | **Ipilimumab**UV1 vaccineGM-CSF | 1/2 | Yes | X |  |  |  |
| NCT02077114 | Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma | **Ipilimumab**IDO-VaccineVemurafenib | 1 | Completed | X |  |  |  |
| NCT00094653 | MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma | **MDX-010**MDX-1379 Melanoma Peptide Vaccine | 3 | Completed | X |  |  |  |
| NCT01988077 | Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients | **Ipilimumab**Adoptive cell transfer | 2 | Yes | X |  |  |  |
| NCT02452281 | Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | **Ipilimumab**HSPPC-96 | 1/2 | Not yet | X |  |  |  |
| NCT01302496 | Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (TriMix-Ipi) | **Ipilimumab**TriMix-DC | 2 | Unknown | X |  |  |  |
| NCT01810016 | NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma | **Ipilimumab**NY-ESO-1 VaccineNY-ESO-1 OLP4 Vaccine | 1 | Yes | X |  |  |  |
| NCT01480323 | A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 | **Ipilimumab**IL-2 | 2 | Completed | X |  |  |  |
| NCT01363206 | Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (GIPI) | **Ipilimumab**GM-CSF | 2 | Ongoing butnot recruiting | X |  |  |  |
| NCT00028431 | Novel Adjuvants for Peptide-Based Melanoma Vaccines | **MDX-CTLA4 Antibody**Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine | 1 | Completed | X |  |  |  |
| NCT00084656 | Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma | **Ipilimumab**Tyrosinase/gp100/MART-1 Peptides | 2 | Completed | X |  |  |  |
| **ID** | **Name** | **Intervention** | **Phase** | **Recruiting/stage** | **Combination of at last one immune checkpoint inhibitor/****co-stimulator with** |
|  | Immunotherapy | Chemo- or Radiotherapy | Targeted therapy | Others |
| NCT00077532 | Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma | **Ipilimumab**gp100 antigen | 2 | Competed | X |  |  |  |
| NCT00032045 | Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma | **Ipilimumab**gp100 antigen | 2 | Completed | X |  |  |  |
| NCT01672450 | A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma | **Ipilimumab**IL-2 | 1 | Completed | X |  |  |  |
| NCT02009397 | A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | **Ipilimumab**GM-CSF | 1/2 | Yes | X |  |  |  |
| NCT00090896 | CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery | **CP-675,206**DC Vaccine | 1 | Completed | X |  |  |  |
| NCT00025181 | Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery | **Ipilimumab**MART-1 antigengp100 antigentyrosinase peptideadjuvant therapy | 1 | Completed | X |  |  |  |
| NCT01740297 | Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | **Ipilimumab**Talimogene laherparepvec | 1/2 | Yes | X |  |  |  |
| NCT02385669 | A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (Mel62; 6PAC) | **Ipilimumab**6MHP | 1/2 | Yes | X |  |  |  |
| NCT01708941 | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | **Ipilimumab**Recombinant IFN-a2b | 2 | Yes | X |  |  |  |
| NCT00610857 | Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma | **Anti-CTLA4 mAb**HDI | 2 | Completed | X |  |  |  |
| NCT00058279 | Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma | **Ipilimumab**Aldesleukin | 1/2 | Completed | X |  |  |  |
| NCT00056134 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | **recombinant CD40L**denileukin diftitoxautologous DCs | 1/2 | Completed | X |  |  |  |
| NCT01189383 | IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma | **CD40L**IL15-DC VaccineLPS | 1/2 | Ongoing butnot recruiting | X |  |  |  |
| NCT01838200 | A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma | **Ipilimumab**Bacillus Calmette-Guérin (BCG) vaccine | 1 | Yes | X |  |  |  |
| NCT01008527 | Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100 | **CP 870,893**PeptidesOncovir poly IC:LC | 1 | Completed | X |  |  |  |
| NCT02112032 | Treatment of Advanced Melanoma With MK-3475 and Peginterferon | **MK-3475**PegIFN-a2b | 1 | Yes | X |  |  |  |
| NCT02339324 | Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b | **Pembrolizumab**HDI |  | Yes | X |  |  |  |
| NCT02327078 | A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | **Nivolumab**INCB24360 | 1/2 | Yes | X |  |  |  |
| NCT00790010 | Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma | **Ipilimumab**Bevacizumab | 1 | Not yet | X |  |  |  |
| NCT02521870 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma | **Pembrolizumab**SD-101 | 1 | Yes | X |  |  |  |
| NCT01489059 | Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma | **Ipilimumab**BMS-982470 | 1 | Completed | X |  |  |  |
| **ID** | **Name** | **Intervention** | **Phase** | **Recruiting/stage** | **Combination of at last one immune checkpoint inhibitor/****co-stimulator with** |
|  | Immunotherapy | Chemo- or Radiotherapy | Targeted therapy | Others |
| NCT01608594 | Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma | **Ipilimumab**HDI-α2b | 1 | Yes | X |  |  |  |
| NCT02210104 | Adoptive Therapy Using Antigen-Specific CD4 T-Cells | **Ipilimumab**CyclophosphamideCD4+ T cells | 1 | Not yet | X | X |  |  |
| NCT01701674 | Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | **Ipilimumab**CyclophosphamideFludarabineTILsHigh Dose Il-2 | n/a | Yes | X | X |  |  |
| NCT01993719 | Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma | **Keytruda**AldesleukinFludarabineCyclophosphamideYoung TILs | 2 | Yes | X | X |  |  |
| NCT02383212 | Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies | **REGN2810**Hypofractionated radiotherapyCyclophosphamide | 1 | Yes | X | X |  |  |
| NCT00871481 | Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma | **Ipilimumab**CyclophosphamidealdesleukinCD8+ T Cells | 1/2 | Completed | X | X |  |  |
| NCT02009449 | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | **Pembrolizumab** AM0010 (hu IL-10)Paclitaxel or Docetaxel and Carboplatin or CisplatinFOLFOX(Oxaliplatin/Leucovorin/5-Fluorouracil)gemcitabine/nab-paclitaxelCapecitabinePazopanib | 1 | Yes | X | X |  |  |
| NCT02027935 | Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 | **Ipilimumab** CyclophosphamideCD8+ T CellsIL-2 | 2 | Yes | X | X |  |  |
| NCT01409174 | IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma | **Ipilimumab**TemozolomideCisplatinIFN-a2bIL-2 | 1/2 | Ongoing butnot recruiting | X | X |  |  |
| NCT02500576 | MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2) | **MK-3475**CyclophosphamideMesnaFludarabineTILs/ IL-2 | 2 | Yes | X | X |  |  |
| NCT01703507 | Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases | **Ipilimumab**Whole-Brain Radiation SRS | 1 | Ongoing butnot recruiting |  | X |  |  |
| **ID** | **Name** | **Intervention** | **Phase** | **Recruiting/stage** | **Combination of at last one immune checkpoint inhibitor/****co-stimulator with** |
|  | Immunotherapy | Chemo- or Radiotherapy | Targeted therapy | Others |
| NCT02407171 | Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC | **MK-3475**SRBT | 1/2 | Yes |  | X |  |  |
| NCT02562625 | Trial of Pembrolizumab and Radiotherapy in Melanoma (PERM) | **Pembrolizumab**Radiotherapy | 2 | Not yet |  | X |  |  |
| NCT02318771 | Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer | **MK-3475**Radiation Therapy | 1 | Yes |  | X |  |  |
| NCT01557114 | Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma (Mel-Ipi-Rx) | **Ipilimumab**Radiotherapy | 1 | Yes |  | X |  |  |
| NCT02115139 | GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases (GRAY-B) | **Ipilimumab**Radiation | 2 | Yes |  | X |  |  |
| NCT01950195 | SRS (Stereotactic Radiosurgery) Plus Ipilimumab | **Ipilimumab**SRS | 1 | Yes |  | X |  |  |
| NCT02406183 | Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma | **Ipilimumab**SBRT | 1 | Yes |  | X |  |  |
| NCT01449279 | Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy | **Ipilimumab**Radiation Therapy | n/a | Yes |  | X |  |  |
| NCT02107755 | Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma | **Ipilimumab**SRS | 2 | Yes |  | X |  |  |
| NCT01497808 | RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma | **Ipilimumab**SRBT | 1/2 | Yes |  | X |  |  |
| NCT01996202 | A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma | **Ipilumimab**Radiation | 1 | Yes |  | X |  |  |
| NCT02303990 | RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers | **Pembrolizumab**Radiotherapy | 1 | Yes |  | X |  |  |
| NCT01676649 | Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma | **Ipilimumab**CarboplatinPaclitaxel | 2 | Ongoing butnot recruiting |  | X |  |  |
| NCT00050102 | Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma | **MDX-010**decarbazine (DTIC) | 2 | Completed |  | X |  |  |
| NCT01740401 | CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma | **Ipilimumab** Cyclophosphamide | 2 | Completed |  | X |  |  |
| NCT00796991 | Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine | **Ipilimumab**CarboplatinPaclitaxelDacarbazine | 1 | Completed |  | X |  |  |
| NCT01590082 | Doxycycline, Temozolomide and Ipilimumab in Melanoma | **Ipilimumab**DoxycyclineTemozolomide | 1/2 | Completed |  | X |  |  |
| NCT02115243 | Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma | **Ipilimumab**Melphalan | 1 | Yes |  | X |  |  |
| NCT01323517 | Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity | **Ipilimumab**MelphalanDactinomycin | 2 | Yes |  | X |  |  |
| NCT02608437 | A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients (NIBIT-M4) | **Ipilimumab**SGI-110 | 1 | Yes |  | X |  |  |
| NCT01119508 | Ipilimumab + Temozolomide in Metastatic Melanoma | **Ipilimumab**Temozolomide | 2 | Ongoing butnot recruiting |  | X |  |  |
| NCT01654692 | A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma (NIBIT-M1) | **Ipilimumab**Fotemustine | 2 | Completed |  | X |  |  |
| NCT01827111 | Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma | **Ipilimumab**ABI-007 | 2 | Yes |  | X |   |  |
| **ID** | **Name** | **Intervention** | **Phase** | **Recruiting/stage** | **Combination of at last one immune checkpoint inhibitor/****co-stimulator with** |
|  | Immunotherapy | Chemo- or Radiotherapy | Targeted therapy | Others |
| NCT02437136 | Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma | **Pembrolizumab** Entinostat | 1b/2 | Not yet |  |  | X |  |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | **Pembrolizumab** PLX3397 | 1/2a | Yes |  |  | X |  |
| NCT02027961 | Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone | **MEDI4736**DabrafenibTrametinib | 1/2 | Yes |  |  | X |  |
| NCT02357732 | Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib | **Nivolumab**TrametinibDabrafenib | 1 | Not yet |  |  | X |  |
| NCT02130466 | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | **Pembrolizumab**DabrafenibTrametinib | 1/2 | Yes |  |  | X |  |
| NCT02400385 | A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma | **Nivolumab**Sunitinib | 2 | Yes |  |  | X |  |
| NCT02298959 | Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors | **Pembrolizumab**Ziv-Aflibercept | 1 | Yes |  |  | X |  |
| NCT02501096 | Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors | **Pembrolizumab** Lenvatinib | 1/2 | Yes |  |  | X |  |
| NCT02141542 | Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma | **Tremelimumab**MEDI3617 | 1 | Yes |  |  | X |  |
| NCT01767454 | Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma | **Ipilimumab**DabrafenibTrametinib | 1 | Ongoing butnot recruiting |  |  | X |  |
| NCT00790010 | Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma | **Ipilimumab** Bevacizumab | 1 | Ongoing butnot recruiting |  |  | X |  |
| NCT01245556 | Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma | **Ipilimumab**BMS-908662 | 1 | Completed |  |  | X |  |
| NCT02200562 | Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma | **Ipilimumab**dabrafenib | 1/2 | Yes |  |  | X |  |
| NCT01738139 | Ipilimumab and Imatinib Mesylate in Advanced Cancer | **Ipilimumab**Imatinib Mesylate | 1 | Yes |  |  | X |  |
| NCT02403778 | Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Stage IV Melanoma | **Ipilimumab**All-Trans Retinoic Acid | 2 | Not yet |  |  |  | X |
| NCT02032810 | Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma | **Ipilimumab** Panobinostat | 1 | Yes |  |  |  | X |
| NCT02557321 | PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma | **Pembrolizumab**PV-10 | 1/2 | Not yet |  |  |  | X |
| NCT02117362 | Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma | **Ipilimumab**GR-MD-02 | 1 | Yes |  |  |  | X |
|  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| **ID** | **Name** | **Intervention** | **Phase** | **Recruiting/stage** | **Combination of at last one immune checkpoint inhibitor/****co-stimulator with** |
|  | Immunotherapy | Chemo- or Radiotherapy | Targeted therapy | Others |
| NCT01689870 | Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | **Anti-OX40****Ipilimumab** | 1/2 | Withdrawn | X |  |  |  |
| NCT00803374 | Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma | **Anti-CD137****Ipilimumab** | 1 | Withdrawn | X |  |  |  |
| NCT01409187 | IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma | **Ipilimumab**IFNAldesleukin | 1/2 | Withdrawn | X |  |  |  |
| NCT00365937 | Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides | **IMP321**Peptides and adjuvantsHLA-A2 peptidesMontanide ISA51 | 1/2 | Terminated(new regulations) | X |  |  |  |
| NCT00357461 | Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma | **Ipilimumab**gp100:209-217(210M) peptide vaccine gp100:280-288(288V) peptide vaccine | 2 | Withdrawn | X |  |  |  |
| NCT01769222 | Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer | **Ipilimumab**radiation therapy | 1/2 | Suspended(DMSC audit results) |  | X |  |  |
| NCT01400451 | Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) | **Ipilimumab** Vemurafenib | 1 | Terminated(toxicity) |  |  | X |  |

**Table 2.** Currently registered clinical trials that combine an immune checkpoint inhibitor/costimulatory molecule with other melanoma treatments from clinicaltrials.gov. Bolded drug names are the immune checkpoint inhibitor/costimulatory molecule being focused on the trial.